References
2. Mannino DM, Kiriz VA. Changing the burden of COPD mortality. Int J Chron Obstruct Pulmon Dis 2006;1(3):219–33.
3. Mannino DM. COPD: epidemiology, prevalence, morbidity and mortality, and disease heterogeneity. Chest 2002;121:121S–26S.
4. Celli BR, MacNee W. Standards for the diagnosis and treatment of patients with COPD: a summary of the ATS/ERS position paper. Eur Respir J 2004;23(6):932–46.
5. Barnes PJ, Hansel TT. Prospects for new drugs for chronic obstructive pulmonary disease. Lancet 2004;364(9438):985–96.
6. Jung SK, Jung HJ, Kim JD, Choi HY, Park MY, Park YC, et al. Pye-gye-nae-gwa-hak Seoul: Nado; 2011. p. 510–1.
7. Lee H, Kim Y, Kim HJ, Park S, Jang YP, Jung S, et al. Herbal Formula, PM014, Attenuates Lung Inflammation in a Murine Model of Chronic Obstructive Pulmonary Disease. Evid Based Complement Alternat Med 2012;2012:769830. Epub 2012 Jun 12.
8. Lee JG, Yang SY, Kim MH, Namgung U, Park YC. Protective effects of Socheongryong-tang on Elastase-Induced Lung Injury. J Korean Oriental Med 2011;32(4):83–99.
9. Yoon JM, Park YC. Protective effects of Seonpyejeongcheon-tang on Elastase-induced Lung Injury. J Korean Oriental Med 2010;31(1):84–101.
10. Choi HJ, Bang NY, Song BW, Kim NJ, Rhyu BH. Survey on the preference for the dosage forms of oriental herbal medicine. Kyunghee Medicine 2004;20(1):46–57.
11. Derendorf H, Nave R, Drollmann A, Cerasoli F, Wurst W. Relevance of pharmacokinetics and pharmacodynamics of inhaled corticosteroids to asthma. Eur Respir J 2006;28(5):1042–50.
12. Courrier HM, Butz N, Vandamme TF. Pulmonary drug delivery systems: recent developments and prospects. Crit Rev Ther Drug Carrier Syst 2002;19(4–5):425–98.
13. Zhang J. Shang-han-za-bing-lun. Shijiazhuang. Hebei Kezue Jishu Chubanshe 1994;:27.
14. Jung S, Cho SJ, Moon KI, Kim HW, Kim BY, Cho SI. Effects of Socheongryong-Tang on Immunoglobulin Production in Asthmatic Mice. Kor. J. Herbology 2008;23(1):23–8.
15. Kim KY, Lee JH, Kim YJ, Choi SY, Kim TH, Lyu YS, et al. Anti-allergic effects of Socheongyoung-tang on RBL-2H3 mast cell and mice-mediated allergy model. Korean J. Oriental Physiology & Pathology 2007;21(5):1260–70.
16. Hwang WS, Lee JS, Choi JY, Jung HJ, Rhee HK, Jung SK. Two Cases of Chronic Sinusitis with Asthma Improved by Socheongryong-tang. J Korean Oriental Med 2003;24(1):207–12.
17. Jung SK, Heo TS, Hwang WS, Ju CY, Kim YW, Jung HJ. The Effects of Sochongryong-tang on Serum IL-4, IL-5, and IFN-ɣ in asthmatic Patients. J Korean Oriental Med 2002;23(2):70–7.
18. Ibrahim BM, Jun SW, Lee MY, Kang SH, Yeo Y. Development of inhalable dry powder formulation of basic fibroblast growth factor. Int J Pharm 2010;385(1–2):66–72.
19. Thiel CG. Cascade impactor data and the log-normal distribution: nonlinear regression for a better fit. J Aerosol Med 2002;15(4):369–78.
20. Nemzek JA, Bolgos GL, Williams BA, Remick DG. Differences in normal values for murine white blood cell counts and other hematological parameters based on sampling site. Inflamm Res 2001;50(10):523–7.
21. Hillery AM, Lloyd AW, Swarbrick J. Drug delivery and targeting; for pharmacists and pharmaceutical scientists London: Taylor and Francis; 2001. p. 2.
22. Tayab ZR, Hochhaus G. Pharmacokinetic/pharmacodynamic evaluation of inhalation drugs: application to targeted pulmonary delivery systems. Expert Opin Drug Deliv 2005;2(3):519–32.
23. Rabe KF, Hurd S, Anzueto A, Barnes PJ, Buist SA, Calverley P, et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. Am J Respir Crit Care Med 2007;176(6):532–55.
24. Geller DE. Comparing clinical features of the nebulizer, metered-dose inhaler, and dry powder inhaler. Respir Care 2005;50(10):1313–21.
25. Borgstrom L. On the use of dry powder inhalers in situations perceived as constrained. J Aerosol Med 2001;14(3):281–7.
26. Yang Y, Tsifansky MD, Shin S, Lin Q, Yeo Y. Mannitol-guided delivery of Ciprofloxacin in artificial cystic fibrosis mucus model. Biotechnol Bioeng 2011;108(6):1441–9.
27. Yang Y, Tsifansky MD, Wu CJ, Yang HI, Schmidt G, Yeo Y. Inhalable antibiotic delivery using a dry powder co-delivering recombinant deoxyribonuclease and ciprofloxacin for treatment of cystic fibrosis. Pharm Res 2010;27(1):151–60.
28. Lipworth BJ. Targets for inhaled treatment. Respir Med 2000;94:S13–6.
29. Azarmi S, Lobenberg R, Roa WH, Tai S, Finlay WH. Formulation and in vivo evaluation of effervescent inhalable carrier particles for pulmonary delivery of nanoparticles. Drug Dev Ind Pharm 2008;34(9):943–7.
30. Molfino NA, Jeffery PK. Chronic obstructive pulmonary disease: Histopathology, inflammation and potential therapies. Pulm Pharmacol Ther 2007;20(5):462–72.
31. Yoo CG. Pathogenesis and pathophysiology of COPD. The Korean Journal of Medicine 2009;77:383–400.
32. Niewoehner DE, Kleinerman J, Rice DB. Pathologic changes in the peripheral airways of young cigarette smokers. N Engl J Med 1974;291(15):755–8.
33. Schaberg T, Haller H, Rau M, Kaiser D, Fassbender M, Lode H. Superoxide anion release induced by platelet-activating factor is increased in human alveolar macrophages from smokers. Eur Respir J 1992;5(4):387–93.
34. Wright JL, Cosio M, Churg A. Animal models of chronic obstructive pulmonary disease. Am J Physiol Lung Cell Mol Physiol 2008;295(1):L1–15.
35. Wright JL, Sun JP. Effect of smoking cessation on pulmonary and cardiovascular function and structure: analysis of guinea pig model. J Appl Physiol 1994;76(5):2163–8.
36. Yang IA, Clarke MS, Sim EH, Fong KM. Inhaled corticosteroids for stable chronic obstructive pulmonary disease. Cochrane Database Syst Rev 2012;7:CD002991.
37. Tanino M, Betsuyaku T, Takeyabu K, Tanino Y, Yamaguchi E, Miyamoto K, et al. Increased levels of interleukin-8 in BAL fluid from smokers susceptible to pulmonary emphysema. Thorax 2002;57(5):405–11.
38. Keatings VM, Collins PD, Scott DM, Barnes PJ. Differences in interleukin-8 and tumor necrosis factor-alpha in induced sputum from patients with chronic obstructive pulmonary disease or asthma. Am J Respir Crit Care Med 1996;153(2):530–4.
39. Demedts IK, Demoor T, Bracke KR, Joos GF, Brusselle GG. Role of apoptosis in the pathogenesis of COPD and pulmonary emphysema. Respir Res 2006;7:53.
40. Foronjy R, D’Armiento J. The role of collagenase in emphysema. Respir Res 2001;2(6):348–52.